Study Finds C₂N Diagnostics’ PrecivityAD® Blood Test Provides Opportunities for Robust Cost Savings in the Evaluation of Patients with Cognitive Impairment

Net savings in the diagnostic work-up of $3.57 million ($0.30 per member per month) in a budget impact model of 1 million member population (11% cost savings)

Over $1 billion savings potential when extrapolated to the U.S. population as a whole

ST. LOUIS--(BUSINESS WIRE)--C₂N Diagnostics’ PrecivityAD blood test, used by healthcare providers to determine Alzheimer’s disease (AD) pathology, has the potential to provide significant cost savings, according to a new study published in Population Health Management. The test helps healthcare providers better determine the presence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease. These measurements are made from a single blood sample.

The new research, “Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment,” used a budget impact model in a hypothetical 1 million-member health plan to assess the economic utility of the PrecivityAD blood test. Investigators from the University of Washington, Washington University in St. Louis and C₂N Diagnostics contributed to this study.

The model compared two scenarios:

• baseline testing involving usual care practice; and
• early use of the PrecivityAD test over the usual diagnosis methods consisting of amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarkers in these regards.

At a modest 40% adoption rate, the PrecivityAD test scenario had comparable sensitivity and specificity to the usual care scenario and showed:

• net savings in the diagnostic work-up of $3.57 million or $0.30 per member per month in a 1-million-member population (11% cost savings);
• savings that translate to over $1 billion when extrapolated to the U.S. population as a whole; and
• savings that were driven by reductions in the frequency and need for PET and CSF testing.

Overall, the PrecivityAD blood test was associated with a cost savings of $643 per Alzheimer’s disease case (9% cost savings) identified.

Dr. Joel Braunstein, C₂N’s CEO, says, “We believe this economic evaluation is an important way to identify the optimal strategies for diagnosing Alzheimer’s disease, which has a substantial economic burden. Over 16 million Americans are living with cognitive impairment and they want a diagnostic evaluation to determine the cause of this disorder. The recent availability of disease-modifying therapies for Alzheimer’s disease is going to drive even more demand for such diagnostic testing. This study on economic utility adds to the broad evidence base of the PrecivityAD blood test, which demonstrates analytic validity, clinical validity and clinical utility. We believe the use of the PrecivityAD blood test in the clinical care pathway may prevent unnecessary testing, provide cost savings and reduce the burden on both patients and health plans.”

About C₂N Diagnostics, LLC

C₂N is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C₂N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C₂N’s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C₂N assays have been used in over 150 Alzheimer’s disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer’s disease. C₂N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer’s Association, and other non-profits and consortiums. Over 15,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.

The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer’s Drug Discovery Foundation, BrightFocus Foundation and Alzheimer’s Association. For more information visit www.C2N.com.